H.C. Wainwright reiterates Buy rating on Monopar stock at $125
H.C. Wainwright reiterated a Buy rating and $125 price target for Monopar Therapeutics (MNPR) as it nears completion of its NDA submission for ALXN1840 in Wilson Disease. The stock trades at $68.05, with a Strong Buy consensus. Clinical data shows improvements in copper balance and neurological symptoms. The company has a strong balance sheet, with a current ratio of 33.56. BTIG raised its target to $133, while Cantor Fitzgerald downgraded to Neutral with a $119 target.
How this was made
The 30-second read
Why it matters
Analyst reiteration may attract short‑term buying but the core clinical milestone has been previously disclosed.
Market read
Modest relevance; primarily an analyst opinion piece with limited new material.
What to watch
Potential regulatory delays or competitive therapies could temper upside despite the analyst's optimism.
Background
Monopar Therapeutics is advancing its ALXN1840 NDA for Wilson Disease; multiple analysts have issued ratings and targets.
Ticker impact
H.C. Wainwright reiterated a Buy rating and raised the price target to $125 for Monopar Therapeutics (MNPR) while the stock trades around $68.
potential upward pressure as investors price in the $125 target versus current levels
The rating and target are new in this article, but the underlying NDA progress has been reported previously, limiting the catalyst strength.
Market effects
Limited; reinforces positive sentiment in the rare‑disease biotech niche.
None
Low
Counterpoint
The stock may already be fully priced for the NDA progress; the higher target may not translate into near‑term price gains.
Key entities
- companyMonopar Therapeutics
Biotech firm developing ALXN1840 for Wilson Disease.
- analyst_firmH.C. Wainwright
Equity research firm that issued the Buy rating.
